Story perspectives

Biogen Acquires Apellis for $5.6 Billion to Boost Portfolio

3/31/2026

Summary

Story summary

Biogen announced its acquisition of Apellis Pharmaceuticals for $5.6 billion, paying $41 per share, to strengthen its immunology and rare disease portfolio.
Apellis' drugs, Syfovre and Empaveli, generated $689 million in revenue last year and are projected for significant growth.
The deal includes a contingent value right for Apellis shareholders, potentially adding up to $4 per share based on sales performance.
Biogen expects to close the transaction in the second quarter of 2026 and plans to utilize Apellis' sales infrastructure for future product launches.

1 of 1

Story summary

Biogen announced its acquisition of Apellis Pharmaceuticals for $5.6 billion, paying $41 per share, to strengthen its immunology and rare disease portfolio.
Apellis' drugs, Syfovre and Empaveli, generated $689 million in revenue last year and are projected for significant growth.
The deal includes a contingent value right for Apellis shareholders, potentially adding up to $4 per share based on sales performance.
Biogen expects to close the transaction in the second quarter of 2026 and plans to utilize Apellis' sales infrastructure for future product launches.